Subscribe To

Price Alert Latest News Economic Calendar News

VECT / VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022, at 1:40 p.m. ET. Company management will also be participating in one-on-one investor meetings at the conference. Read More

Demo Live Account See Partner Details

Content Topics

Vectivbio

Present

Leerink

11th

Annual

Global

Healthcare

Conference

Stock

VECT

Posted: Feb 8 2022, 07:15

Author Name: GlobeNewsWire

VECT News

By The Motley Fool
May 22, 2023

Why Shares of VectivBio Holding Are Up Today

Ironwood Pharmaceuticals' buyout deal is worth $1 billion. The attraction was VectivBio's late-stage therapy, apraglutide.

By Investors Business Daily
May 22, 2023

VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion

Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock skidded.

By Barrons
May 22, 2023

Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion

Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company.

By Market Watch
May 22, 2023

Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion

Ironwood Pharmaceuticals Inc. IRWD, +2.45% said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT, +8.18% for $17 a share in cas

By Seeking Alpha
April 17, 2023

VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts

By GlobeNewsWire
November 9, 2022

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical compan

By Seeking Alpha
April 7, 2022

VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript

By GlobeNewsWire
February 8, 2022

VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical compan

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.